<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086866</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-16032-18031</org_study_id>
    <secondary_id>EORTC-18031</secondary_id>
    <secondary_id>EORTC-16032</secondary_id>
    <secondary_id>GSK-249553/008</secondary_id>
    <secondary_id>2004-001937-40</secondary_id>
    <nct_id>NCT00086866</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery</brief_title>
  <official_title>Randomized, Open Phase II Study of Immunization With the Recombinant MAGE-3 Protein Combined With Adjuvant AS02B or AS15 in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying two different regimens of vaccine therapy&#xD;
      and comparing them to see how well they work in treating patients with stage III or stage IV&#xD;
      melanoma that cannot be removed with surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the objective response rate (complete and partial response) in patients with&#xD;
           unresectable stage III or stage IV M1a cutaneous melanoma immunized with vaccine&#xD;
           comprising D1/3-MAGE-3-His fusion protein and SB-AS02B adjuvant vs SB-AS15 adjuvant.&#xD;
&#xD;
        -  Compare the activity of SB-AS02B adjuvant vs SB-AS15 adjuvant, in terms of maximizing&#xD;
           the antigenicity of MAGE-3, in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the rate of grade 3/4 vaccine-related toxicity in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare progression-free survival in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open label, parallell-group, multicenter study. Patients are&#xD;
      stratified according to disease stage (III in transit vs other stage III vs IV), presence of&#xD;
      lesion ≥ 20 mm (yes vs no), and participating center. Patients are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Induction therapy&#xD;
&#xD;
             -  Arm I: Patients receive immunization comprising D1/3-MAGE-3-His fusion protein and&#xD;
                SB-AS02B adjuvant intramuscularly (IM) once weekly on weeks 1, 3, 5, 7, 9, and 11.&#xD;
&#xD;
             -  Arm II: Patients receive immunization comprising D1/3-MAGE-3-His fusion protein&#xD;
                SB-AS15 adjuvant IM once weekly on weeks 1, 3, 5, 7, 9, and 11.&#xD;
&#xD;
      Patients achieving a clinical complete response (CR), partial response (PR), stable disease&#xD;
      (SD), or slow progressive disease (SPD) proceed to maintenance therapy.&#xD;
&#xD;
        -  Maintenance therapy: Patients in both arms receive immunization (according to their&#xD;
           randomized arm) once weekly on weeks 15, 18, 21, 24, 27, 30, 34, 40, 46, and 52.&#xD;
&#xD;
      Patients maintaining a CR, PR, or SD proceed to long-term treatment.&#xD;
&#xD;
        -  Long-term treatment: Beginning 3 months after completion of maintenance therapy,&#xD;
           patients in both arms receive immunization (according to their randomized arm) once&#xD;
           every 3 months for 4 courses and then once every 6 months for 4 courses.&#xD;
&#xD;
      Treatment continues in both arms in the absence of disease progression that does not&#xD;
      correspond to SPD status, unacceptable toxicity, or the diagnosis of an autoimmune disease.&#xD;
&#xD;
      Patients are followed every 12 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 68 patients (34 patients per treatment arm) will be accrued for&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2004</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (complete response and partial response) as assessed by RECIST criteria</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine-related toxicity as assessed by CTCAE v3</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of stabilization as assessed by RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of mixed response as assessed by RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of immune response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <enrollment type="Actual">165</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>D1/3-MAGE-3-His fusion protein</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB-AS02B adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB-AS15 adjuvant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed cutaneous melanoma&#xD;
&#xD;
               -  Unresectable stage III OR stage IV M1a disease&#xD;
&#xD;
          -  Documented progressive disease within the past 12 weeks&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Skin, soft tissue, or lymph node metastasis allowed provided the disease is not&#xD;
             amenable to curative treatment with surgery&#xD;
&#xD;
          -  Tumor must express the MAGE-3 gene by reverse transcription polymerase chain reaction&#xD;
             analysis (more than 1% of the positive MAGE-3 control included in the assay)&#xD;
&#xD;
          -  No visceral metastases within the past 56 days by imaging&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin ≥ lower limit of normal (LLN)&#xD;
&#xD;
          -  WBC ≥ LLN&#xD;
&#xD;
          -  Lymphocyte count ≥ LLN&#xD;
&#xD;
          -  Platelet count ≥ LLN&#xD;
&#xD;
          -  No bleeding disorders&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ upper limit of normal (ULN)&#xD;
&#xD;
          -  Lactic dehydrogenase ≤ ULN&#xD;
&#xD;
          -  AST and ALT ≤ 2 times ULN&#xD;
&#xD;
          -  PT and aPTT normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative (antibody test may be positive)&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No clinically significant heart disease (CTC grade III or IV)&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No autoimmune disease (vitiligo allowed)&#xD;
&#xD;
          -  No anti-nuclear antibody titer ≥ 1/320 OR equal to 1/160 AND auto-antibodies directed&#xD;
             against specific auto-antigens&#xD;
&#xD;
          -  No immunodeficiency&#xD;
&#xD;
          -  No active infection requiring antibiotic therapy&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No other malignancy within the past 5 years except surgically cured basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other serious acute or chronic illness requiring concurrent medications&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 8 weeks since prior adjuvant vaccine therapy&#xD;
&#xD;
          -  No prior vaccine therapy containing a MAGE-3 antigen&#xD;
&#xD;
          -  No prior vaccine therapy for metastatic melanoma&#xD;
&#xD;
          -  No concurrent immunomodulating agents (e.g., BCG)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior systemic chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
               -  Concurrent prednisone or equivalent allowed provided the dose is ≤ 40 mg/day and&#xD;
                  treatment duration is for no more than 3 weeks&#xD;
&#xD;
               -  Concurrent inhaled and topical steroids are allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the spleen&#xD;
&#xD;
          -  No concurrent radiotherapy to &gt; 20% of all existing lesions (i.e., target lesions,&#xD;
             non-target lesions, and nonmeasurable lesions)&#xD;
&#xD;
               -  Concurrent local low-dose (≤ 20 Grays) radiotherapy allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery or biopsy&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
          -  Concurrent surgery to a limited number of lesions allowed for patients with a complete&#xD;
             response, partial response, or stable disease after at least 3 courses of study&#xD;
             therapy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior systemic anticancer therapy&#xD;
&#xD;
          -  More than 4 weeks since prior isolated limb perfusion therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent immunosuppressive agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Willem H. J. Kruit, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Daniel Den Hoed Cancer Center at Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cornelis J. A. Punt, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Medisch Centrum St. Radboud - Nijmegen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte-Marguerite</name>
      <address>
        <city>Hyeres</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional et Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital St. Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>D-12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>D-97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Siena</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Kruit WH, Suciu S, Dreno B, et al.: Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031). [Abstract] J Clin Oncol 26 (Suppl 15): A-9065, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Louahed J, Gruselle O, Gaulis S, et al.: Expression of defined genes identified by pretreatment tumor profiling: association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). [Abstract] J Clin Oncol 26 (Suppl 15): A-9045, 2008.</citation>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

